For the 2022 MAGIC Revisions, still in progress, we are deeply indebted for the advice and assistance of Dr. Aaron Gerds, Dr. Richard T. Silver., Dr. Ruben Mesa, Dr. Srdan Verstovsek, Dr. John Mascarenhas, Dr. Claire Harrison, Dr. Abu Zaineh Ghaith, Dr. Joseph Scandura, Dr. Claire Harrison, Dr. Zorah Nooruddin, and Helen Chovestide, PhD.
The MAGIC MPN risk assessment tool grew out of the work of the MPN stem cell transplantation taskforce (MS3T). (See listing of members, below.)
Fo r high risk myelofibrosis patients with rapidly progressing disease, the only cure may be a stem cell transplant. The timing of the SCT is critical and too often MF patients delay the procedure until the onset of blast phase of progression to Acute Myeloid Leukemia where the outcomes are unfavorable. Internationally renowned hematologists, transplanters, pathologists, teamed up with MPN patient advocates to focus on this issue.
The conclusion: A simple, free, graphically striking on-line tool that incorporated current findings on myelofibrosis assessment could help reduce the toll resulting from delay of stem cell transplant.
The MS3T reviewed the clinically validated DIPSS and DIPSS+ scales that measured myelofibrosis risk levels and consulted on the construction of the Stem Cell Transplant Timing Tool (SSTT, http://www.mpntransplant.com/)
The same scoring scales and risk assessment that applied to SCT timing is applicable to prognostic application in myelofibrosis as an aid to determining levels of treatment, from Watch & Wait or low level intervention in low risk MF to SCT or entry to clinical trial for higher risk levels. Adapting the SCT tool to the general MF population was a natural extension of the Taskforce’s work.
The addition of mutational burden added an extra dimension to the tool. MAGIC simply lists and totals mutations. The mutation analysis section is integrally linked to “Notes on MPN Mutations,”here and in the MPN Quarterly Journal The Notes provide more detail on the most common MPN mutations and a general background on the MPN mutational landscape..
In July , 2021 the MPN-SAF. myeloproliferative neoplasm system assessment form , was added to MAGIC to provide parallel insights into the ET and PV phenotypes and provide additional information on the impact of symptoms on the assessment of MF.
The MPN Research Foundation was a major sponsor of this work as part of its myelofibrosis and SCT education and patient support programming.
The MPN Research Foundation launch announcement to media is here.
Members, MS3T
Hematologists
Dr. Claire Harrison
Professor and Clinical Director, Guy’s and St. Thomas’ Hospital London
Dr. Ruben Mesa
Director, Mays Cancer Center of UT Health San Antonio MD Anderson Cancer Center
Dr. Richard T. Silver
Professor of Medicine, Weill-Cornell
Richard T Silver MD Myeloproliferative Neoplasms Center
Dr. Srdan Verstovsek
Department of Leukemia, UT MD Anderson Cancer Center, Houston
Transplant specialists
Dr. Koen Van Besien
Director, SCT program, Weill-Cornell
Dr. Nicolaus Kroeger
Medical Director, SCT, University Hospital, Hamburg
Dr. Jeanne Palmer
Medical Director, BMT, Mayo Clinic, Phoenix
Dr. Uday Popat
Professor Dept of SCT, MD Anderson
Hematopathologist
Dr. Attilio Orazi
Professor of Pathology, Director of Hematopathology, Weill-Cornell
Adjunct Advisor
Dr. Wael Saber
Scientific Director, CIBMTR, Associate Professor
Medical College of Wisconsin
MPN SCT Patients
Chris Harper
Beatrice Larroque
Martin Prager
MPN Patient Advocates
Ann Brazeau
MPN Advocacy and Education, CEO
Ann Haehn
President and Founder, Genny’s Hope Foundation
Barbara Van Husen
CEO, MPN Research Foundation
Michelle Woerhle
Director, MPN Research Foundation
Project Director
Zhenya Senyak
Editor & Publisher, MPN Quarterly Journal/MPNforum
Sponsor:
The MPN Research Foundation
Special thanks to the MS3t Taskforce and to Ed Bartholemy, Diane Blackstock, Zeta Charania, John Crispino, David Denny, Brandon Goetz, Jacob Grinfeld, Claire Harrison, Ruben Mesa, Pam Murphy, Jerry Spivak . Ann Mallally and William Vainchenker. Dedicated to the memory of Robert Rosen.
For the 2022 Revisions , still progressing, we are deeplyy indebted for the iput and assistance of Dr. Richard T. Silver, Dr. Ruben Mesa, Dr. Srdan Verstovsek, Dr. Claire Harrison, Dr. Aaron Gerds, Dr. Koen Van Besien, Dr. Nicolaus Kroeger, Dr. Joseph Scandura, Dr.Zorah Nooruddin \, Abu Zaineh Ghaith , and Helen Chofestides PhD. All remaining errors and omissions are attributable to the editors..